No Change Statement and Notice of Annual General Meeting – 9 December 2020 ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (“Aspen Holdings”) Registration number: 1985/002935/06 Share code: APN ISIN: ZAE000066692 LEI: 635400ZYSN1IRD5QWQ94 and its subsidiaries (collectively “Aspen” or “the Group”) NO CHANGE STATEMENT AND NOTICE OF ANNUAL GENERAL MEETING – 9 DECEMBER 2020 1. POSTING OF AGM NOTICE AND ABBREVIATED REPORT Shareholders are advised that the Company’s Integrated Report for the year ended 30 June 2020 has been finalised and that the abbreviated report and the notice of the annual general meeting (“AGM”) to be held at its Durban offices on 9 December 2020 is being posted to shareholders. The following documents have been posted online at the Company’s website www.aspenpharma.com (at the following link https://www.aspenpharma.com/investor-information/): - Integrated Report for the 2020 financial year; Notice of AGM and proxy in respect of the AGM to be held on 9 December 2020; - Unabridged Corporate Governance Statement and reports of the Aspen Audit & Risk and Social & Ethics committees for the 2020 financial year; - Annual Financial Statements for the 2020 financial year (“AFS”); and - Various other reports supplementary to the Integrated Report. The AFS contain no modifications to the reviewed provisional results which were published on SENS on 9 September 2020. The AFS were audited by PricewaterhouseCoopers Inc. Their unqualified report, along with an originally signed copy of the AFS, is available for inspection at the Company’s registered office. 2. NOTICE OF AGM Notice is hereby given that the 22nd annual general meeting of the shareholders of the Company will be held at Aspen Place, 9 Rydall Vale Park, Douglas Saunders Drive, La Lucia Ridge Office Park, Durban, Kwa-Zulu Natal, on Wednesday, 9 December 2020 at 10:00. Should you choose to attend the meeting in person, please ensure that you contact the Company Secretary & Group Governance Officer at rverster@aspenpharma.com / 031 580 8624 by no later than 10:00 on Monday, 7 December 2020 in order to ensure compliance with COVID-19 regulations and requirements. The record date on which a person must be registered as a shareholder in the register of the Company for purposes of being entitled to attend and participate in, and speak and vote at, the meeting is Friday, 27 November 2020. Accordingly, the last day to trade in order to be registered in the register of members of the Company and therefore be eligible to participate in and vote at the annual general meeting is Tuesday, 24 November 2020. Shareholders are requested, but are not obliged, to submit their completed forms of proxy to the Company’s transfer secretaries (Link Market Services) before 10:00 on Monday, 7 December 2020. Shareholders who, for whatever reason, experience postal delays and who do not receive the notice of the AGM in time to submit proxy forms to the Company’s share transfer secretaries (Link Market Services) are requested to access the notice of AGM and other documents referred to above on the Company’s website www.aspenpharma.com. A printable version of these documents in PDF format can also be emailed to shareholders upon request to the Company Secretary – rverster@aspenpharma.com or +27 31 580 8624. Electronic participation Shareholders or their proxies or representatives may participate in (but not vote at) the meeting by way of telephone/ video conference call, and if they wish to do so: • Must contact the Company Secretary & Group Governance Officer (by email at the address rverster@aspenpharma.com) by no later than 10:00 on Friday 27 November 2020 in order to obtain the dial-in details / meeting link in order to participate in the meeting; • Will be required to provide reasonably satisfactory identification; and • Will be billed separately by their own service providers for the costs incurred in respect of their telephone/ video call to participate in the meeting. 3. BROAD-BASED BLACK ECONOMIC EMPOWERMENT CERTIFICATE Shareholders are hereby notified that in accordance with the JSE Listings Requirements, the Company's B-BBEE compliance report in terms of section 13G(2) of the Broad-Based Black Economic Empowerment Act 53 of 2003 read with the Broad-Based Black Economic Empowerment Act 46 of 2013, is in the process of being submitted to the BEE Commission and will be made available on the Company’s website www.aspenpharma.com as soon as the submission process has completed. A further announcement in this regard will be made to shareholders. Durban 28 October 2020 Sponsor Investec Bank Limited Date: 28-10-2020 05:50:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.